An optimal two-stage phase II design utilizing complete and partial response information separately

Controlled Clinical Trials

Volumn 23, Issue 4, 2002, Pages 367-379

  Panageas, Katherine S ^a   Smith, Alex ^a   Gönen, Mithat ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Optimal; Phase II; Trinomial

Indexed keywords

ARTICLE; CANCER SURVIVAL; CLASSIFICATION; CLINICAL PRACTICE; COMPUTER PROGRAM; EXPERIMENTAL DESIGN; ONCOLOGY; PARAMETER; PHASE 2 CLINICAL TRIAL; PROBABILITY; SAMPLE SIZE; TREATMENT OUTCOME; TUMOR VOLUME;

CLINICAL TRIALS, PHASE II; HUMANS; MODELS, STATISTICAL; NEOPLASMS; RESEARCH DESIGN;

EID: 0036344705     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(02)00217-9     Document Type: Article

References (19)

1. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
2. Optimal two-stage designs for phase II clinical trials
3. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
5. One sample multiple testing procedure for phase II clinical trials
6. Incorporating toxicity considerations into the design of two-stage phase II clinical trials
7. Bivariate sequential designs for phase II trials
8. Designs for phase II trials allowing for a tradeoff between response and toxicity
9. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials
10. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes
11. Optimal designs for a grouped sequential binomial test
12. A Bayesian approach to the design of phase II clinical trials
13. Predictive probability early termination plans for phase II clinical trials
14. Optimal flexible designs in phase II clinical trials
15. Multinomial phase II cancer trials incorporating response and early progression
16. Application of a new multinomial phase II stopping rule using response and early progression
17. Sample size and design considerations for phase II clinical trials with correlated observations
18. Optimal two-stage designs for phase II clinical trials with differentiation of complete and partial responses
19. A three-outcome design for phase II clinical trials